These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32629158)

  • 1. Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
    Maddah M; Mandegar MA; Dame K; Grafton F; Loewke K; Ribeiro AJS
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106895. PubMed ID: 32629158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued exposure of anti-cancer drugs to human iPS cell-derived cardiomyocytes can unmask their cardiotoxic effects.
    Sakamoto K; Sakatoku K; Sugimoto S; Iwasaki N; Sano Y; Yamaguchi M; Kurokawa J
    J Pharmacol Sci; 2019 Aug; 140(4):345-349. PubMed ID: 31521491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes.
    Grimm FA; Iwata Y; Sirenko O; Bittner M; Rusyn I
    Assay Drug Dev Technol; 2015 Nov; 13(9):529-46. PubMed ID: 26539751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.
    Rajasingh S; Isai DG; Samanta S; Zhou ZG; Dawn B; Kinsey WH; Czirok A; Rajasingh J
    Acta Pharmacol Sin; 2018 Oct; 39(10):1590-1603. PubMed ID: 29620051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.
    Grafton F; Ho J; Ranjbarvaziri S; Farshidfar F; Budan A; Steltzer S; Maddah M; Loewke KE; Green K; Patel S; Hoey T; Mandegar MA
    Elife; 2021 Aug; 10():. PubMed ID: 34338636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells.
    Csöbönyeiová M; Polák Š; Danišovič L
    Can J Physiol Pharmacol; 2016 Jul; 94(7):687-94. PubMed ID: 27128322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
    Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
    Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
    Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes.
    Burnett SD; Blanchette AD; Grimm FA; House JS; Reif DM; Wright FA; Chiu WA; Rusyn I
    Toxicol Appl Pharmacol; 2019 Oct; 381():114711. PubMed ID: 31425687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes.
    Matsui T; Miyamoto K; Yamanaka K; Okai Y; Kaushik EP; Harada K; Wagoner M; Shinozawa T
    Toxicol Appl Pharmacol; 2019 Nov; 383():114761. PubMed ID: 31533062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
    Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
    Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.
    Oleaga C; Riu A; Rothemund S; Lavado A; McAleer CW; Long CJ; Persaud K; Narasimhan NS; Tran M; Roles J; Carmona-Moran CA; Sasserath T; Elbrecht DH; Kumanchik L; Bridges LR; Martin C; Schnepper MT; Ekman G; Jackson M; Wang YI; Note R; Langer J; Teissier S; Hickman JJ
    Biomaterials; 2018 Nov; 182():176-190. PubMed ID: 30130706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
    Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
    Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening.
    Ovics P; Regev D; Baskin P; Davidor M; Shemer Y; Neeman S; Ben-Haim Y; Binah O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023024
    [No Abstract]   [Full Text] [Related]  

  • 20. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
    Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
    Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.